PA-PPG
23.6.2022 16:02:04 CEST | Business Wire | Press release
PPG (NYSE:PPG) today announced that it will dedicate July 2022 to completing more than 25 colorful and transformative school makeovers through its New Paint for a New Start initiative, which is part of PPG’s COLORFUL COMMUNITIES® program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005057/en/
Through New Paint for a New Start, PPG employees from every region will volunteer their time to transform classroom environments to serve local students. Using PPG paint products and color expertise, each project aims to create engaging spaces for students to learn and grow.
“Throughout July, we’re creating opportunities, fresh starts and new beginnings with revitalized spaces to celebrate students and educators and help students feel excited, supported and ready to learn,” said Malesia Dunn, executive director, PPG Foundation and Corporate Global Social Responsibility. “As students and teachers embrace in-person learning after the challenges presented by the COVID-19 pandemic over the last two years, we have identified educational spaces in need of a bright and beautiful refresh, and empowered our employees to carry out those projects.”
Most of the transformation projects will use a single global color palette that PPG color experts specifically selected to elevate physical classroom environments.
“PPG understands that color can enhance learning and create spaces where students feel comfortable and encouraged,” said Kiersten Lent, PPG color and design manager, architectural coatings. “We carefully selected colors that pair with the learning objectives for each classroom while considering factors that include students’ ages and local, cultural influences. The palette includes Olive Sprig, which is the 2022 PPG Color of the Year, or regional colors inspired by it to create a soft, flexible basis for any educational environment.”
In addition to painting spaces, PPG and the PPG Foundation are also supplying several New Paint for a New Start schools with funding for science, technology, engineering and mathematics (STEM) supplies. It is anticipated that more than 1,000 volunteers will participate throughout the month, and PPG and the PPG Foundation will invest nearly $1 million in classroom makeovers and STEM grants.
“Building better, brighter communities often starts with students,” said Henrik Bergström, PPG vice president, Architectural Coatings, Latin America, Europe, Middle East and Africa, and Australia and New Zealand, and New Paint for a New Start executive champion. “We know that many students around the world face educational inequities. When we see outdated classrooms in disrepair, we see our role in creating inspiring spaces that are equipped with the right resources so every student can learn and thrive.”
The Colorful Communities program, PPG’s signature initiative for supporting communities, aims to protect and beautify the neighborhoods where PPG operates around the world. Through the Colorful Communities program, PPG’s committed volunteers contribute their time and PPG paint products to help transform community assets – from painting classrooms, to bringing color to a maternity ward and redesigning a playground. Since 2015, PPG has completed more than 386 Colorful Communities projects, impacting more than 7.4 million people in 42 countries.
PPG’s global community engagement efforts and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We invested $13.3 million in 2021, supporting hundreds of organizations across more than 40 countries. By investing in educational opportunities, we help grow today’s skilled workforce and develop tomorrow’s innovators in fields related to coatings and manufacturing. Plus, we empower PPG employees to multiply their impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more at communities.ppg.com .
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
We protect and beautify the world is a trademark and Colorful Communities and the PPG Logo are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Community Affairs
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
